Trial Profile
"PSOGEN:Effect adalimumab op zelfbeeld en seksueel functioneren bij matige en ernstige psoriasis van de anogenitale regio; prospectief, open label pilot onderzoek"
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 Mar 2013
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Acronyms PSOGEN
- Sponsors Abbott Laboratories
- 17 Jun 2011 Planned End Date changed to 1 Oct 2011 as reported in the European Clinical Trials Registry record.
- 16 Jun 2011 New trial record